A topical oral solution combining the antiseptic and disinfectant properties of Benzoxonium Chloride with the local anesthetic action of Lidocaine. Primarily used for symptomatic relief of pain and inflammation associated with various oropharyngeal conditions. Benzoxonium Chloride is a quaternary ammonium compound effective against a broad spectrum of Gram-positive and Gram-negative bacteria, fungi, and some viruses. Lidocaine provides rapid-onset, short-duration anesthesia of the mucous membranes.
Adult: Gargle or rinse with 5-10 ml (1-2 teaspoonfuls) for about 30 seconds, 3-4 times daily, preferably after meals and at bedtime. Do not swallow.
Note: Use undiluted. Measure the dose. Gargle thoroughly, ensuring contact with the throat, or rinse around the mouth. Spit out completely after use. Avoid eating or drinking for at least 15-30 minutes after application to allow the medicine to work. Do not use for more than 7 days without medical advice.
The combination provides dual action: Lidocaine reversibly blocks voltage-gated sodium channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, leading to local anesthesia. Benzoxonium Chloride disrupts microbial cell membranes through its cationic surfactant properties, leading to leakage of cytoplasmic constituents and cell death.
Pregnancy: Category B (US FDA). No well-controlled studies in pregnant women. Use only if clearly needed, after consulting a physician. Topical application with minimal systemic absorption is generally considered low risk.
Driving: Unlikely to affect ability. However, if systemic absorption causes dizziness or blurred vision, avoid operating machinery.
| Other Local Anesthetics | Additive systemic toxicity risk if used concurrently on large areas. | Moderate |
| Antiarrhythmics (e.g., Amiodarone, Mexiletine) | Increased risk of cardiac adverse effects (bradycardia, arrhythmias). | Moderate |
| CYP1A2 & CYP3A4 Inhibitors (e.g., Ciprofloxacin, Fluconazole, Erythromycin) | May increase systemic Lidocaine levels, increasing toxicity risk. | Moderate |
| Beta-blockers (e.g., Propranolol) | May reduce hepatic blood flow, increasing Lidocaine levels. | Moderate |
| Succinylcholine | Benzoxonium Chloride, as a quaternary ammonium compound, may potentiate neuromuscular blockade. | Theoretical/Low |
Same composition (Benzoxonium Chloride (2.5mg/5ml) + Lidocaine (2.5mg/5ml)), different brands: